



INTERNATIONAL JOURNAL OF
RADIATION ONCOLOGY • BIOLOGY • PHYSICS

www.redjournal.org



One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer

Chelain R. Goodman, MD, PhD,^{*} and Jonathan B. Strauss, MD, MBA[†]

^{*}Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; and [†]Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

Received Feb 18, 2022; Accepted for publication Feb 21, 2022

A 52-year-old woman presented with invasive ductal carcinoma of the left breast, cT3 (5.5 cm) cN1 (single axillary level 1 lymph node) cM0, grade 2, estrogen receptor (ER)-positive (70%) progesterone receptor (PR)-negative (0%) Her2/*neu*-nonamplified. Bone scan obtained at time of diagnosis revealed two lesions within the sternum (1.8 cm × 1.6 cm) and manubrium (2.9 cm × 4.6 cm; Fig. 1). The patient received upfront chemotherapy (dose-dense adriamycin, cyclophosphamide, and paclitaxel) with interval imaging demonstrating partial response in the breast and nodes, and sclerosis of the lytic lesions suggesting response to treatment. She underwent breast conserving surgery and axillary lymph node dissection, revealing 1.8 cm of residual invasive disease in the breast and a 4 mm macrometastasis in one of nine axillary nodes without extranodal extension, ypT1c (1.8 cm) ypN1a (1/9) without extranodal extension.

The patient completed adjuvant external beam radiation therapy and was initiated on anastrozole anti-endocrine therapy. She remained without evidence of disease for 12 years, at which time she was incidentally found to have a nodule in the left upper lobe of the lung. Biopsy confirmed metastatic carcinoma consistent with breast primary, ER-positive PR-negative Her2/*neu*-nonamplified. She completed 12 months of palbociclib and letrozole, with recent reimaging demonstrating no new sites of disease, but further enlargement of the lung nodule to 1.5 cm (Fig. 2).

Corresponding author: Chelain R. Goodman, MD, PhD; E-mail: crgoodman@mdanderson.org

Disclosures: none.

CME is available for this feature as an ASTRO member benefit, to access visit <https://academy.astro.org>.



Fig. 1. Bone scan obtained at time of initial breast cancer diagnosis in 2008, demonstrating uptake within a 1.8 cm × 1.6 cm lesion in the sternum and a 2.9 cm × 4.6 cm in the manubrium.




Fig. 2. Diagnostic computed tomography scan at time of recent reimaging following 12 months of palbociclib and letrozole systemic therapy, demonstrating enlargement of the 1.5-cm nodule in the left upper lobe of the lung.

Questions

Q1: Do you agree with the decision to offer surgery followed by radiation therapy to a patient with oligometastatic disease to the sternum/manubrium? If so, what would be your recommended radiation therapy technique, volumes, and dose(s)?

Q2: Would you recommend surgery and/or radiation therapy for the left upper lung lesion? If not, what treatment, if any, would you recommend?

Q3: What kind of surveillance examinations would you recommend for this patient? If she were to ask you her prognosis, what would be reasonable to tell her?



GRAY ZONE EXPERT OPINIONS

Little Downside



Our approach would include sequential review of this case at multidisciplinary tumor board.¹ For patients with de novo oligometastatic disease with sustained response to therapy, we would consider radiation therapy (RT) after surgery, although the benefits from primary surgery and induction chemotherapy are unclear. Retrospective data suggested similar outcomes for patients with metastatic breast cancer limited to sternum/mediastinum treated with curative-intent and those with IIIC disease.² For this patient, along with hormone therapy, we would offer 50 Gy in 25 fractions RT to the breast, regional nodes, and sternal disease with deep-inspiratory breath-hold, volumetric modulated arc radiation therapy, and lumpectomy cavity boost. Given the unresected sternal disease, we would consider a 10 to 16 Gy sequential sternal boost.

This patient presented with a single metastatic focus after a long disease-free-interval on aromatase inhibitor therapy alone, then received the same class of hormone therapy (suboptimal) combined with a cyclin-dependent kinase 4/6 inhibitor. We would favor stereotactic body radiation therapy (SBRT) over surgery for local control, and change in systemic therapy; the impact of this approach on survival is unclear. We use a risk-adapted approach for SBRT to lung metastases,³ with ablative doses used for early-stage lung cancer. For this noncentral, non-chest wall location, 1 to 3 fractions may be feasible. Surveillance includes periodic body imaging on next line hormone therapy driven by next generation sequencing, considering further targeted agents. We would tell her that she has incurable but indolent disease with additional treatment options, but that resistance to therapy will develop over time. In her case, safe, risk-adapted SBRT offers little downside.

Lisa Singer, MD, PhD
Department of Radiation Oncology
University of California San Francisco
San Francisco, California

Hope S. Rugo, MD
Department of Medicine
University of California San Francisco
San Francisco, California

Disclosures: L.S. received research funding from Viewray and UCSF PIPE, outside the scope of this work. L.S. serves on the Board of Directors for ABMRS and in the Viewray Breast Research Consortium. HR reports research funding from for clinical trials through the University of California: Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Sermonix, Polyphor, Astra Zeneca, OBI, Gilead, Ayala, Astellas, and honoraria from Puma, Samsung and Napo.

References

1. Goodman CR, Strauss JB, et al. One way or another: An oligorecurrence after an oligometastasis of an estrogen receptor-positive breast cancer. *Int J Radiat Oncol Biol Phys* 2022;114:571–572.
2. Christopherson K, Lei X, Barcenas C, et al. Outcomes of curative-intent treatment for patients with breast cancer presenting with sternal or mediastinal involvement. *Int J Radiat Oncol Biology Phys* 2019;104:574–581.
3. Singer L, Kann BH, Cagney DN, Leeman JE, Yom SS, Kozono D. Actualizing risk-adapted thoracic stereotactic body radiation therapy with MR guidance. *Appl Rad Oncol* 2021;10:6–14.

<https://doi.org/10.1016/j.ijrobp.2022.04.014>

A Tale of Competing Risk Management



At the initial presentation,¹ she was oligometastatic, and treatment to achieve durable local control to the left breast, regional nodes, and sternum and manubrium oligometastases could be justified under SABR-COMET.² Given its proximity to the internal mammary nodal chain, we recommend inclusion of the oligometastatic lesion within the breast and comprehensive regional nodal field (50 Gy in 25 fractions) and simultaneous integrated boost to the sternum and manubrium up to 66 Gy, using VMAT with DIBH or proton radiation therapy if available.

After a significant disease-free interval, she has persistent biopsy-proven ER+ lung metastasis, without other competing health risks. Aggressive local management with radiation therapy may cytereduce her cancer burden, although there is presently less mature evidence to support this approach.³ SBRT to

the left lung lesion would be our preferred approach in lieu of surgical management given the relatively lower risk, and clinical trial enrollment would be offered. 54 Gy in 3 fractions would be prescribed using IMRT, with 4DCT motion management, and PTV coverage of $D_{95\%} \geq 100\%$ Rx. With prior lung dose from initial radiation therapy, we recommend accounting for the cumulative EQD2 of lung V20.

Computed tomographic imaging of the lung is recommended every 3 to 4 months after SBRT, as well as surveillance with whole body positron emission tomography/computed tomography to monitor tumor activity, particularly bone lesions that may present as sclerosis. Metastatic disease is not considered curable as participants in oligometastatic clinical trials do eventually progress. However, based on the phenotype of her recurrence, we are hopeful she will live more years with durable disease control, assuming absence of competing health risks.

Oluwadamilola T. Oladeru, MD, MA, MBA
Department of Radiation Oncology
University of Florida
Gainesville, Florida

Divya Yerramilli, MD, MBE
Precision Radiation for Oligometastatic and Metastatic Disease
(PROMISE) Program
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures: O.T.O. reports funding unrelated to the submitted work from Radiation Oncology Institute, NRG Oncology, and Bristol Myers Squibb Foundation.

References

1. Goodman CR, Strauss JB, et al. One way or another: An oligorecurrence after an oligometastasis of an estrogen receptor-positive breast cancer. *Int J Radiat Oncol Biol Phys* 2022;114:571–572.
2. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial. *J Clin Oncol* 2020;38:2830–2838.
3. Chmura SJ, Winter KA, Al-Hallaq HA, et al. NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557). *J Clin Oncol* 2019;37(15 suppl):TPS1117.

<https://doi.org/10.1016/j.ijrobp.2022.03.024>

disease in the setting of an estrogen-receptor expressing (ER+) primary which portends a favorable long-term prognosis in the stage IV setting, further supported by the radiographic response of bony lesions and the absence of additional metastatic spread.

LRT to the primary in metastatic breast cancer (MBC) is controversial as 2 randomized studies have shown lack of survival and/or quality of life benefit to resecting +/-irradiating the primary site.^{2,3} Importantly, these studies included patients with a higher burden of metastatic disease and a heterogeneous mix of receptor statuses—populations with much poorer prognoses than the patient in question. In contrast, a large meta-analysis found a 31.8% reduction in mortality when LRT was employed⁴ and suggested that patients with bone-only MBC and good response to systemic therapy may derive particular benefit.

We would treat the left breast, undissected axilla, and supraclavicular/internal mammary lymph node basins (regional nodal irradiation [RNI]) with 3-dimensional-conformal RT using a deep inspiration breath hold technique. Recent experiences have demonstrated safety and convenience of moderate hypofractionation when treating whole breast irradiation + RNI. Treatment to 42.56 Gy/16 fractions to whole breast irradiation + RNI is now offered on the MA.39/Tailor RT trial, and it has become our institutional practice to offer 16-fraction courses in this setting.

We would consider including the sternum/manubrium lesions in the tangent fields if feasible without causing unacceptable dose to the heart/lungs; conversion to an intensity modulated radiation therapy plan could be considered if necessary. NRG-BR001 used 30 Gy/3 fx for osseous metastases which, using an alpha/beta of 10, is an equivalent dose in 2 Gy fractions (EQD2) = 50 Gy. However, if using alpha/beta of 4, the EQD2 = 70 Gy for 30 Gy/3 fx while EQD2 = 47.24 Gy for 42.56 Gy in 16 fx. Thus, one could also consider boosting the sternum/manubrial lesions if concern for residual disease, upwards of an additional 10 Gy/4 fx.

2. The growth of this lesion represents oligoprogression while on otherwise effective systemic therapy, and should receive local treatment. We would recommend stereotactic body radiation therapy (SBRT) to the lung metastasis. Metastasectomy can be useful to confirm malignancy/reassess receptor patterns, but as this had already been ascertained via biopsy SBRT offers a less invasive and equally effective option.

An exciting and growing body of literature supports aggressive management of oligometastases. Recently, the landmark phase II randomized SABR-COMET trial confirmed an OS benefit when ablative RT was delivered to all sites of disease in the setting of a controlled primary, and NRG-BR001 has established 45 Gy/3 fx as a safe dose for peripheral lung metastases. More recently, the SAFFRON II trial of pulmonary oligometastases has also shown promising results when SBRT is delivered in a single fraction, further increasing patient convenience. Other 3- to 5-fraction SBRT regimens achieving a BED10 ≥ 100 Gy would also be

The Best Defense is a Good Offense



1. We agree with early locoregional therapy (LRT).¹ This patient presented with low-volume, bone-only metastatic

reasonable. We await the results of NRG-BR002 to further inform on the role of metastasis-directed SBRT in MBC.

3. As she has already experienced 2 instances of metastatic disease, we would recommend systemic imaging with positron emission tomography–computed tomography or computed tomography chest/abdomen/pelvis, every 3 to 6 months for 2 years from recurrence. With modern therapies, median survival for de novo ER + MBC may approach 5 years;⁵ given her time to progression, a similar estimate may be reasonable.

Cristina M. DeCesaris, MD

Kristine Kokeny, MD

Department of Radiation Oncology

Huntsman Cancer Institute

Salt Lake City, Utah

Disclosures: none.

References

1. Goodman CR, Strauss JB, et al. One way or another: An oligorecurrence after an oligometastasis of an estrogen receptor-positive breast cancer. *Int J Radiat Oncol Biol Phys* 2022;114:571–572.
2. Khan SA, Zhao F, Goldstein LJ, et al. Early local therapy for the primary site in de novo stage IV breast cancer: Results of a randomized clinical trial (EA2108). *J Clin Oncol* 2022;40:978–987.
3. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. *Lancet Oncol* 2015;16:1380–1388.
4. Gera R, Chehade HELH, Wazir U, Tayeh S, Kasem A, Mokbel K. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis. *Sci Rep* 2020;10:1–11.
5. Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: Meta-analysis and systematic review. *JNCI Cancer Spectr* 2018;2:pkv06.

<https://doi.org/10.1016/j.ijrobp.2022.03.023>

Stage IV or Locally Advanced Disease?



Randomized stage IV breast cancer trials have shown no survival benefit for surgical removal of the primary. However, metastases to the sternum and mediastinum may represent a locoregional process. A retrospective review¹ of breast cancer

patients with limited sternal or mediastinal metastases reported no significant difference in local control, recurrence, or survival compared with patients with stage IIIC disease.² An argument can be made to reclassify these patients as locally advanced, similar to the shift in staging for supraclavicular metastases from M1 to N3c in the sixth edition of the American Joint Committee on Cancer staging system. Definitive comprehensive radiation is recommended to the chest wall, draining nodal basins, and involved sternum/manubrium, to 50 Gy in 25 fractions, followed by a sternal boost of 10 to 16 Gy in 5 to 8 fractions, with dose dependent on imaging response to neoadjuvant treatment. Thoracic surgery consultation is recommended for consideration of metastasectomy.

The Consolidative Use of Radiotherapy to Block (CURB) study assessed stereotactic body radiation therapy (SBRT) for oligoprogression in non-small cell lung cancer and breast cancer.³ Surprisingly, SBRT led to a significant progression-free survival benefit for non-small cell lung cancer (44 vs 9 weeks), but not breast cancer (18 vs 17 weeks). Although a subset of patients may benefit from SBRT, it requires further study. Treatment would only be recommended as part of a trial studying SBRT for oligometastatic disease.

Computed tomography scans of the chest, abdomen and pelvis every 3 months is recommended, similar to the surveillance for the ongoing AVATAR (Audiovisual-Assisted Therapeutic Ambiance in Radiation Therapy) trial. Retrospective studies suggest 3-year survival may be $\geq 50\%$ in this situation.

Melissa P. Mitchell, MD, PhD

University of Texas MD Anderson Cancer Center

Houston, Texas

E-mail address: mpmitchell@mdanderson.org

Disclosures: none.

References

1. Goodman CR, Strauss JB, et al. One way or another: An oligorecurrence after an oligometastasis of an estrogen receptor-positive breast cancer. *Int J Radiat Oncol Biol Phys* 2022;114:571–572.
2. Christopherson K, Lei X, Barcenas C, et al. Outcomes of curative-intent treatment for patients with breast cancer presenting with sternal or mediastinal involvement. *Int J Radiat Oncol Biol Phys* 2019;104:574–581.
3. Tsai CJ, Yang JT, Guttmann DM, et al. Consolidative Use of Radiotherapy to Block (CURB) oligoprogression – Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast. *Int J Radiat Oncol Biol Phys* 2021;111:1325–1326.

<https://doi.org/10.1016/j.ijrobp.2022.03.012>

ChatGPT-4: Comprehensive and Individualized Approach

User: You are an expert radiation oncologist from an academic center.

Please give your recommendation on the following case:

“ ... ”

Please give a specific recommendation of your most favored therapeutic approach in this patient case based on the available information and your reasoning for it.

ChatGPT-4: Based on the available information, my recommendation for this patient with a history of invasive ductal carcinoma, who developed a solitary metastatic lung nodule 12 years after initial treatment and showed progression on palbociclib and letrozole therapy, would be to consider the following approach:

- Stereotactic body radiotherapy (SBRT) for the solitary lung nodule: Since there is a solitary metastatic lesion in the lung that has enlarged despite systemic therapy, local treatment with SBRT could be considered. SBRT is a highly focused radiation therapy that delivers high doses of radiation to small, well-defined tumors, such as the lung nodule in this case. This approach could help control the local disease, potentially offering long-term disease control, and is associated with fewer side effects compared to conventional radiation therapy.
- Re-evaluate systemic therapy: As the lung nodule showed progression on the current palbociclib and letrozole regimen, a re-evaluation of the systemic treatment plan should be considered. This may involve a multidisciplinary discussion with a medical oncologist to determine the most appropriate course of action. It is possible that alternative therapies, such as switching to a different CDK4/6 inhibitor or considering other targeted therapies (e.g., PI3K inhibitors or mTOR inhibitors), may be beneficial in controlling the disease. Additionally, evaluation for potential actionable mutations through genomic profiling could provide further options for targeted therapy.
- Close follow-up and monitoring: After the implementation of the above strategies, it is crucial to closely monitor the patient for any signs of disease progression or recurrence. This should involve regular imaging and clinical evaluations. Any new lesions or progression of disease should be managed promptly with appropriate interventions.

In summary, my recommendation for this patient would be to consider SBRT for the lung nodule, re-evaluate the systemic therapy plan, and maintain close follow-up and monitoring. This approach aims to achieve local control of the solitary lung metastasis, potentially improve systemic disease control, and provide ongoing surveillance for any further disease progression.

User: Do you agree with the decision to offer surgery followed by radiation therapy to a patient with oligometastatic disease to the sternum/manubrium? If so, what would be your recommended radiation therapy technique, volumes, and dose(s)?

ChatGPT-4: In the setting of oligometastatic disease, such as the case presented, local treatments like surgery and radiation therapy can be considered in addition to systemic therapy. The rationale

for treating oligometastatic lesions is to achieve better local control, potentially delay further progression, and possibly prolong survival. However, the specific treatment approach should be individualized based on the patient's performance status, extent of disease, and potential benefits versus risks.

If the decision is made to offer surgery followed by radiation therapy for the oligometastatic lesions in the sternum/manubrium, I would recommend the following radiation therapy technique, volumes, and doses:

- **Technique:** Intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) should be used. These advanced radiation therapy techniques allow for precise delivery of radiation to the target volume while minimizing the dose to surrounding normal tissues. This is particularly important when treating areas such as the sternum/manubrium, which are in proximity to critical structures such as the lungs, heart, and esophagus.
- **Volumes:** The treatment volumes should include the gross tumor volume (GTV), which represents the visible tumor on imaging, and a clinical target volume (CTV) expansion to cover any potential microscopic disease spread. An additional margin should be added to create the planning target volume (PTV) to account for uncertainties in patient positioning and setup during treatment. The radiation oncologist will determine the appropriate margins based on the patient's specific anatomy and tumor characteristics.
- **Doses:** The recommended radiation dose will depend on the specific clinical scenario, including tumor size, location, and proximity to critical structures. Generally, for oligometastatic disease in bone, a dose of 30-45 Gy delivered in 10-15 fractions is commonly used. However, the radiation oncologist will need to consider the patient's prior treatment history, the dose that the surrounding normal tissues can tolerate, and any potential dose constraints to determine the most appropriate dose regimen.

In conclusion, offering surgery followed by radiation therapy for oligometastatic disease to the sternum/manubrium can be a reasonable approach in select patients. The choice of radiation therapy technique, volumes, and doses should be individualized based on the patient's specific clinical scenario and anatomy, with an emphasis on minimizing the risk of toxicity to the surrounding normal tissues.

User: Would you recommend surgery and/or radiation therapy for the left upper lung lesion? If not, what treatment, if any, would you recommend?

ChatGPT-4: In the case of the left upper lung lesion, given its solitary nature and progression despite systemic therapy, I would recommend considering local treatment options. While surgery is a potential option, I would first consider stereotactic body radiotherapy (SBRT) for the following reasons:

- Minimally invasive: SBRT is a non-invasive treatment option that can be highly effective for small, well-defined lung lesions. It offers the advantage of avoiding the potential complications and morbidity associated with surgery, such as pain, bleeding, and infection.
- Precision: SBRT allows for the precise delivery of high doses of radiation to the target volume while sparing surrounding healthy tissues. This can lead to better local control of the lesion with fewer side effects compared to conventional radiation therapy.
- Efficacy: SBRT has been shown to be highly effective in treating small, solitary lung metastases, with local control rates often exceeding 90%. This makes it an attractive option for managing isolated metastatic lesions.

If SBRT is not feasible due to the lesion's location or other patient-specific factors, surgical resection could be considered, especially if the patient is a good surgical candidate with adequate pulmonary function and minimal comorbidities. The choice between these two treatment modalities should be based on multidisciplinary discussions involving the radiation oncologist, medical oncologist, and thoracic surgeon, taking into account the patient's overall health, preferences, and potential benefits and risks of each option.

In addition to local treatment of the lung lesion, it is crucial to re-evaluate the patient's systemic therapy, as the lesion showed progression on the current palbociclib and letrozole regimen. This may involve considering alternative therapies, such as switching to a different CDK4/6 inhibitor or exploring other targeted therapies based on actionable mutations identified through genomic profiling.

In summary, I would recommend considering SBRT for the left upper lung lesion, followed by a re-evaluation of systemic therapy. The choice between SBRT and surgery should be based on a thorough discussion with the multidisciplinary team and the patient's preferences and overall health.

User: What kind of surveillance examinations would you recommend for this patient? If she were to ask you her prognosis, what would be reasonable to tell her?

ChatGPT-4: For this patient, after completing the recommended local and systemic treatments, a regular surveillance program should be established to closely monitor her for any signs of disease progression or recurrence. The surveillance examinations may include:

- Clinical evaluations: Regular physical examinations and clinical assessments, including a breast exam, should be performed every 3-6 months for the first 2 years, and then every 6-12 months thereafter.

- Mammography: Annual mammography of the ipsilateral (treated) and contralateral (untreated) breasts should be performed to screen for local recurrence or new primary breast cancers.
- Imaging studies: Periodic imaging studies, such as chest CT scans and/or whole-body PET/CT scans, may be considered to monitor for any signs of recurrent or metastatic disease. The frequency of these studies will depend on the patient's individual risk factors, response to treatment, and clinical presentation.
- Blood tests: Periodic blood tests, including complete blood count (CBC) and liver function tests, can be useful to monitor the patient's overall health and the potential side effects of ongoing systemic therapies.

As for the patient's prognosis, it is essential to acknowledge that prognostication in cancer is complex and depends on numerous factors, such as the tumor's biology, stage, response to treatment, and individual patient factors. Given that she has already experienced a recurrence after 12 years of being disease-free, her prognosis may be considered somewhat favorable compared to patients with earlier recurrences. However, the recent progression of the lung nodule on systemic therapy is a concerning factor.

While it's not possible to provide an exact prognosis, it is reasonable to inform the patient that her disease is manageable with appropriate treatments and close monitoring. Emphasize the importance of adhering to the recommended surveillance program and maintaining open communication with her healthcare team to promptly address any new symptoms or concerns.

It is crucial to provide support and reassurance while acknowledging the uncertainty that comes with cancer treatment and prognosis. Encourage her to discuss her fears and concerns openly, and remind her that the healthcare team will be working closely with her to optimize her care and manage her disease as effectively as possible.

User: Please summarize the four experts' recommendations in short sentences.

ChatGPT-4: Expert 1: Recommends sequential review at a multidisciplinary tumor board, radiation therapy after surgery, stereotactic body radiation therapy (SBRT) for the lung nodule, and a change in systemic therapy with risk-adapted SBRT.

Expert 2: Advocates for aggressive local management with radiation therapy for both initial presentation and lung nodule, including VMAT with DIBH or proton radiation therapy if available, and SBRT for the lung lesion. Suggests periodic CT and PET/CT scans for surveillance.

Expert 3: Supports early locoregional therapy (LRT), including 3D-conformal RT and potential boosting of the sternum/manubrium lesions. Recommends SBRT for lung metastasis and systemic imaging every 3 to 6 months for 2 years from recurrence.

Expert 4: Considers reclassification of the patient as locally advanced, recommends definitive comprehensive radiation for chest wall, draining nodal basins, and involved sternum/manubrium, followed by sternal boost. Suggests thoracic surgery consultation for metastasectomy consideration and CT scans for surveillance every 3 months.

User: As an expert radiation oncologist, which of the above four experts' recommendation do you think the most proper for the patient described above?

ChatGPT-4: As an expert radiation oncologist, I find the approach recommended by Expert 3 to be the most comprehensive and suitable for this patient. This approach includes:

1. Early locoregional therapy (LRT) with 3D-conformal RT using deep inspiration breath hold technique for the left breast, undissected axilla, and regional nodal basins. Potential boosting of the sternum/manubrium lesions if feasible, and
2. Stereotactic body radiation therapy (SBRT) for the lung metastasis, which offers a less invasive and equally effective option compared to surgery, and
3. Systemic imaging with PET-CT or CT scans of the chest, abdomen, and pelvis every 3 to 6 months for 2 years from recurrence to monitor the patient's condition.

This approach accounts for the patient's history and the current status of the disease while providing a balanced treatment plan that addresses both the primary breast cancer and the lung metastasis. It is important, however, for the patient's case to be discussed in a multidisciplinary tumor board setting to ensure the most appropriate and individualized treatment plan is developed.

User: At the beginning, you said that "my recommendation for this patient would be to consider SBRT for the lung nodule, re-evaluate the systemic therapy plan, and maintain close follow-up and monitoring.." In this case, which expert's recommendation is your initial suggestion closest to?

ChatGPT-4: My initial recommendation is closest to Expert 3's recommendation. Both Expert 3 and my initial suggestion involve:

1. Early locoregional therapy for the breast cancer and nodal regions.
2. Stereotactic body radiation therapy (SBRT) for the lung metastasis as a less invasive and equally effective option compared to surgery.
3. Re-evaluating the systemic therapy plan and maintaining close follow-up and monitoring.

Expert 3's recommendation provides more detailed information regarding the radiation therapy technique, dose, and fractionation, as well as the specific follow-up strategy, but the core concepts and treatment approach align well with my initial suggestion.

User: After seeing the other experts' recommendations, are you going to update your own recommendation of your most favored therapeutic approach in this patient case? If so, what is your updated recommendation and which expert/experts is your update based on?

ChatGPT-4: After reviewing the other experts' recommendations, I would like to update my initial recommendation to be more comprehensive, incorporating aspects of Expert 3's approach. My updated recommendation for this patient would be:

1. Early locoregional therapy (LRT) with 3D-conformal RT using deep inspiration breath hold technique for the left breast, undissected axilla, and regional nodal basins. Potential boosting of the sternum/manubrium lesions if feasible.
2. Stereotactic body radiation therapy (SBRT) for the lung metastasis, offering a less invasive and equally effective option compared to surgery.
3. Re-evaluate the systemic therapy plan in consultation with the patient's medical oncologist to optimize treatment effectiveness.
4. Systemic imaging with PET-CT or CT scans of the chest, abdomen, and pelvis every 3 to 6 months for 2 years from recurrence to monitor the patient's condition.

This updated recommendation is primarily based on Expert 3's approach, as it provides a balanced and comprehensive treatment plan, addressing both the primary breast cancer and the lung metastasis. It is important to discuss the patient's case in a multidisciplinary tumor board setting to ensure the most appropriate and individualized treatment plan is developed.